← The Wire
FDMTNasdaq
4D Molecular Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1650648
Advancing durable, disease-targeted gene therapies for ophthalmology, cardiology, and pulmonology
$462M
Market cap
$12.88
Last close
+11.0%
1D
+23.6%
5D
1.5M
Volume
Price · last 39 sessions+36.4%
May 4L $8.37 · H $12.88Jun 29
122
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · New Debt / ObligationJun 29, 20268-KShareholder VoteJun 22, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KExecutive ChangeMar 30, 202610-K10-KMar 18, 20268-KResults of OperationsMar 18, 20268-KEquity IssuanceJan 26, 20268-KExecutive Change · Results of OperationsJan 7, 20268-KCompany UpdateDec 10, 20258-KExecutive ChangeNov 17, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KCompany UpdateNov 7, 2025424B5424B5Nov 6, 20258-KResults of Operations · Company UpdateNov 6, 20258-KMaterial AgreementOct 31, 20258-KExecutive Change · Bylaw AmendmentOct 2, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 20258-KExecutive Change · Company UpdateJul 2, 20258-KShareholder VoteJun 20, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 202510-K10-KFeb 28, 20258-KResults of OperationsFeb 28, 20258-KCompany UpdateFeb 10, 20258-KResults of Operations · Company UpdateJan 10, 20258-KEquity IssuanceDec 11, 202410-Q10-QNov 13, 20248-KResults of OperationsNov 13, 2024SC 13GSC 13GNov 6, 2024SC 13GSC 13GNov 4, 20248-KCompany UpdateSep 18, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KReg FD DisclosureJul 23, 20248-KCompany UpdateJul 17, 20248-KMaterial AgreementJun 7, 2024424B5424B5Jun 7, 20248-KShareholder VoteMay 24, 20248-KResults of OperationsMay 9, 202410-Q10-QMay 9, 2024DEFA14ADEFA14AApr 10, 2024DEF 14ADEF 14AApr 10, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 29, 20248-KCompany UpdateFeb 9, 2024424B5424B5Feb 8, 2024424B5424B5Feb 5, 20248-KExecutive ChangeJan 4, 20248-KBylaw AmendmentNov 22, 20238-KResults of OperationsNov 9, 202310-Q10-QNov 9, 20238-KExecutive ChangeSep 13, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 9, 20238-KMaterial AgreementJul 11, 2023SC 13GSC 13GJun 5, 20238-KShareholder VoteMay 25, 2023SC 13GSC 13GMay 15, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 20238-KCompany UpdateMay 9, 2023424B5424B5May 8, 2023424B5424B5May 4, 2023DEFA14ADEFA14AApr 12, 2023DEF 14ADEF 14AApr 12, 20238-KResults of OperationsMar 15, 202310-K10-KMar 15, 20238-KCompany UpdateFeb 3, 20238-KCompany UpdateJan 26, 20238-KResults of OperationsNov 9, 202210-Q10-QNov 8, 20228-KExecutive ChangeSep 27, 20228-KResults of OperationsAug 11, 2022
Insider Activity
In the 90 days to Mar 20, 2026: 1 sold $7K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 20, 2026 | Gupta AshooVP, Finance and Controller | Sell | 310 | $8.61 | $3K |
| Mar 20, 2026 | Gupta AshooVP, Finance and Controller | Sell | 80 | $8.61 | $689 |
| Dec 20, 2025 | Gupta AshooVP, Finance and Controller | Sell | 310 | $8.68 | $3K |
| Dec 20, 2025 | Gupta AshooVP, Finance and Controller | Sell | 79 | $8.68 | $686 |
| Dec 16, 2025 | Bizily ScottChief Legal Officer | Sell | 1,635 | $10.90 | $18K |
| Nov 17, 2025 | Bizily ScottChief Legal Officer | Sell | 1,635 | $10.59 | $17K |
| Oct 24, 2025 | Bizily ScottChief Legal Officer | Sell | 2,678 | $12.00 | $32K |
| Oct 16, 2025 | Bizily ScottChief Legal Officer | Sell | 1,635 | $10.17 | $17K |
| Oct 9, 2025 | Bizily ScottChief Legal Officer | Sell | 2,408 | $10.00 | $24K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance